MetaCap

Evommune Inc. (EVMN)

NYSE: EVMNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

7.04-0.20 (-2.76%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

EVMN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$291.10M
EPS (TTM)
-$3.83
52-week range
4.94 – 33.20
Day range
6.96 – 7.24
Volume / Avg
549.40K / 841.65K
Beta
—
Next earnings
Dec 10, 2026

52-week range

$4.94$33.20

EVMN stock today

Shares of Evommune (EVMN) finished lower on Nov 20 at $7.04, a drop of 2.76% or $0.20 per share, versus the S&P 500's 3.70% decline. At this level, EVMN sits near the bottom of its 52-week range of $4.94 to $33.20: 78.8% below the high, set on Feb 10, 2026 and 42.5% above the low. EVMN is down 58.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 62.4%.

Evommune has posted a net loss over the last twelve months (EPS of -$3.83), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Dec 10; analysts expect EPS of -$0.82.

Summary generated from market data by MetaCap's automated system. Methodology

About Evommune

Company profile

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Luis C. Pena
Headquarters
Palo Alto, CA
Employees
48
IPO year
2025

Financial highlights

Full financials

In fiscal 2025, Evommune generated $13.0 million in revenue, up 85.7% from fiscal 2024. Evommune reported a net loss of $68.9 million, compared with a loss of $66.8 million a year earlier. Operating margin was -623.6%.

Evommune annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024
Revenue$13.00M$7.00M
Growth+85.71%—
Net income$-68.87M$-66.81M
EPS (diluted)$-11.22$-45.29

Analyst forecast

Forecast

Consensus (12 analysts)

buy

Avg. price target

$21.89+210.94%

  • Strong buy 4
  • Buy 5
  • Hold 3
  • Sell 0
  • Strong sell 0

Target range

Low $8.00High $28.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Dec 10, 2026
EPS estimate
$-0.82
Last reported (Sep/2026)
Dec 10, 2026
EPS actual vs est.
$-0.85 vs $-0.82
Surprise
-3.66%

EVMN news

All EVMN news

Evommune peers

Health Care sector
EVMN peer companies
CompanyPrice% ChgMarket capCompare
BNTCBenitec Biopharma Inc.7.92-2.76%$285.88Mvs EVMN
SPRYARS Pharmaceuticals Inc.2.96-11.90%$297.56Mvs EVMN
GLSIGreenwich LifeSciences Inc.19.25-2.73%$282.56Mvs EVMN
FULCFulcrum Therapeutics Inc.3.69-0.54%$281.85Mvs EVMN
RLMDRelmada Therapeutics Inc.2.62-15.76%$279.54Mvs EVMN
GALTGalectin Therapeutics Inc.2.69-4.27%$271.35Mvs EVMN
VCREVicore Pharma Holding AB ADR9.41-5.09%$264.89Mvs EVMN
AVIRAtea Pharmaceuticals Inc.3.96+0.76%$318.00Mvs EVMN

Indexes, lists and sector

Evommune stock FAQ

What is Evommune's stock price today?

EVMN last traded at $7.04 as of Nov 20, 4:00 PM EST, down 2.76% on the day. Prices are delayed at least 15 minutes.

When is Evommune's next earnings date?

Evommune is expected to report earnings on Thursday, December 10, 2026. Analysts expect EPS of $-0.82.

Who is Evommune's CEO?

Mr. Luis C. Pena is the chief executive officer of Evommune Inc., which has about 48 employees.

What is the EVMN 52-week high?

The 52-week high for EVMN is $33.20 and the 52-week low is $4.94. The stock is currently 78.8% below its high.

Compare EVMN